Home / Market News / $TLX
benzinga Corporate Catalyst Impact 55/100 ● neutral

HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target

Sep 25, 2026, 2:29 PM UTC · Primary ticker $TLX

This filing discloses that HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating and maintained a $20 price target for Telix Pharmaceuticals. This indicates continued analyst confidence in the company's prospects, which could provide some positive sentiment for investors.

HC Wainwright & Co. analyst Robert Burns has reaffirmed a 'Buy' rating and a $20 price target for Telix Pharmaceuticals. This action signals that the analyst's outlook on the company's fundamentals and future performance remains unchanged and positive. For Telix Pharmaceuticals, this reiteration can help maintain investor confidence and potentially support its stock price in the short term. While not a new catalyst, it reinforces existing positive sentiment. The key opportunity for traders is that this continued analyst support might prevent significant downward pressure on the stock, and could be seen as a validation of its current valuation or growth trajectory.

$TLX positive Analyst reiterates Buy rating and price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.